Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 17/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 16/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7919153 | 0.86 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNA6 | |
| SCHEMBL7931224 | 0.84 | CHRNB2 (0.71) | CHRNB2CHRNA4 | |
| SCHEMBL7919152 | 0.83 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA6 | |
| SCHEMBL3359010 | 0.83 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA6 | |
| SCHEMBL7925434 | 0.83 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA6 | |
| SCHEMBL3358897 | 0.82 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA6 | |
| SCHEMBL7935637 | 0.82 | CHRNB2 (0.70) | CHRNB2CHRNA4 | |
| SCHEMBL7931067 | 0.81 | CHRNB2 (0.69) | CHRNB2CHRNA4 | |
| SCHEMBL3357814 | 0.80 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA6 | |
| SCHEMBL7928226 | 0.80 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010045212-A2 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INCSTATUTS (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | CHRNB2 12/4885CHRNA4 5/4885CHRNB4 15/4885 |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | CHRNB2 12/4885CHRNA4 5/4885CHRNB4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.